Drug Profile
Anti-EGFR chimeric antigen receptor T cell therapy - CARsgen Therapeutics
Alternative Names: CAR-EGFR/EGFRvIII T; CSG-EGFRLatest Information Update: 28 May 2020
Price :
$50
*
At a glance
- Originator CARsgen
- Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Cancer; Glioblastoma
Most Recent Events
- 28 May 2020 No recent reports of development identified for phase-I development in Glioblastoma(In the elderly, Recurrent, Second-line therapy or greater, In adults) in China (Parenteral)
- 28 Mar 2020 No recent reports of development identified for preclinical development in Cancer in China (Parenteral)
- 21 Mar 2018 Phase-I development is ongoing in China (CARSGEN pipeline, March 2018)